Natural products derived from plants, as well as their bioactive compounds, have been extensively studied in recent years for their therapeutic potential in a variety of neurodegenerative diseases (NDs), including Alzheimer’s (AD), Huntington’s (HD), and Parkinson’s (PD) disease. These diseases are characterized by progressive dysfunction and loss of neuronal structure and function. There has been little progress in designing efficient treatments, despite impressive breakthroughs in our understanding of NDs. In the prevention and therapy of NDs, the use of natural products may provide great potential opportunities; however, many clinical issues have emerged regarding their use, primarily based on the lack of scientific support or proof of their effectiveness and patient safety. Since neurodegeneration is associated with a myriad of pathological processes, targeting multi-mechanisms of action and neuroprotection approaches that include preventing cell death and restoring the function of damaged neurons should be employed. In the treatment of NDs, including AD and PD, natural products have emerged as potential neuroprotective agents. This current review will highlight the therapeutic potential of numerous natural products and their bioactive compounds thatexert neuroprotective effects on the pathologies of NDs.

Butyl-fructooligosaccharides (B-FOSs) are newly synthesized prebiotics composed of short-chain FOS (GF2, 1-kestose; GF3, nystose; GF4, fructofuranosyl-nystose; GF5, 1-F-(1-b-D-fructofuranosyl)-2-nystose) bound with one or two butyric groups by ester bonds. Previous in...

Redox imbalance in intestinal epithelial cells is critical in the early phases of intestinal injury. Dysfunction of the intestinal barrier can result in immunological imbalance and inflammation, thus leading to intestinal syndromes and associated illnesses. Several antioxidants have been discovered to be beneficial in resolving intestinal barrier dysfunction. Of these antioxidants, the effects of alkaline reduced water (ARW) in oxidative stress of intestinal epithelial cells and its immunokine modulation in vitro is unknown. In this study, we utilized ARW-enriched media to investigate its cytoprotective effect against H2O2-induced oxidative stress in DLD1 cells. We found that ARW rescued DLD1 from oxidative stress by diluting the influence of H2O2 on oxidative stress-activated MAPK signaling and mitochondrial dysfunction. Further, intestinal oxidative stress significantly affects immunokine profiles of Raw 264.7 cells (IL-6, IL-10, MCP, TNF-a, RANTES), which can be reversed by ARW. Collectively, ARW shields intestinal epithelial cells from oxidative stress, reducing the immunological mayhem caused by barrier failure.

Whitening materials cannot easily cross the skin barrier (stratum corneum) to reach melanocytes in the basal layer for inhibiting melanin production. This study aims to construct a novel deformable liposome using polyglyceryl‐3‐methylglucose distearate as an edge activator and a hydrogel containing hyaluronic acid (HA) and hydroxyethyl cellulose (HEC), as well as to investigate the synergistic effect of this system on the delivery of a cysteine derivative, methyl‐2‐acetylamino‐3‐(4‐hydroxyl‐3,5‐dimethoxybenzoylthio)propanoate (MP) as a whitening agent. The optimized deformable liposome (DL2) contains 10% edge activator and has a particle size of 78.2 ± 2.7 nm, a zeta potential of −29.9 ± 1.8 mV, a polydispersity index of 0.248, and an entrapment efficiency of 90.7 ± 1.7%. MP‐loaded DL2 has higher stability and deformability than DL2 without MP, as well as exerting a higher whitening effect than that observe with MP alone. In addition, MP‐loaded DL2 is incorporated into a hydrogel in a dual drug‐delivery system and the stability after hydrogel incorporation is evaluated. In Franz cells, the MP‐loaded deformable liposome‐hydrogel complex shows the highest skin permeation and penetration of MP. Practical Applications: In general, it is very difficult for whitening agents to penetrate a skin layer for reducing skin pigmentation. It is important to transfer whitening agents to the basal layer without causing physical damage to the skin. Deformable liposomes containing 10% polyglyceryl‐3‐methylglucose distearate in a hydrogel complex maximize the skin permeation of a cysteine derivative as a whitening agent. This finding indicates that the deformable liposome‐hydrogel complex is a potential delivery system for treatment of skin hyperpigmentation. The penetration mechanism of drugs in the skin by deformable liposome‐hydrogel complexes is as follows: Hydrogel hydrates stratum corneum to secure the route of drugs or nanocarrier permeation. polyglyceryl‐3‐methylglucose distearate as an edge activator enhances the fluidity of the stratum corneum lipid layer and the deformability of liposome. The edge activator‐based deformable liposomes pass through the stratum corneum stably.

A well-known functional gastrointestinal disorder called functional dyspepsia (FD) is defined by dyspeptic symptoms without any structural abnormalities. In alternative intervention, electrolyzed alkaline-reduced water (EARW) consumption is regarded as a treatment modality for gastrointestinal symptoms despite its mechanism not yet fully understood. The present clinical study aimed to investigate the effects of EARW on gastrointestinal symptoms of patients with FD. Forty-eight participants with FD were screened, and 42 were enrolled. Participants were randomly allocated to the EARW (n = 21) and purified water (PW) (n = 21) groups. The EARW group ingested EARW (10 mL/kg body weight/day) for 6 weeks. The gastrointestinal symptom rating scale (GSRS), functional dyspepsia-related quality of life (FD-QoL), the Korean version of the Nepean Dyspepsia Index (NDI-K) were used as primary outcome measures at baseline and at 6 weeks, and inflammatory markers were measured as the secondary outcome. Two participants dropped out, and 40 participants (EARW = 20 and PW = 20) completed the trial. Total GSRS score was significantly lower in the EARW group (34.27%, p < 0.01) than in the PW (18.16%) group. In the five subcategories of GSRS, the decreased score between baseline and post-intervention for the EARW and PW groups were 43.59% and 21.33% in abdominal pain score, respectively; 38.98% and 18.92% in reflux syndrome, respectively; 25.42% and 20.90% in diarrhea, respectively; 35.87% and 21.48% in indigestion, respectively; and 32.81% and 10.71% in constipation, respectively, and all the parameters were significantly different in the EARW group compared with those in the PW group. The NDI-K score was also lower in the EARW group (p < 0.01) than in the PW group. FD-QoL score decreased significantly more in the EARW group after intervention than in the PW group (p < 0.05). Additionally, inflammatory cytokines (TNF-α and IFN-γ) levels significantly suppressed in the EARW group after 6 weeks of drinking compared with the levels at the baseline. Our clinical study suggests that long-term drinking of EARW (pH 9.5) may improve FD-related symptoms and the quality of life of FD patients through home-based administration.